TrialRheumatology international2026

LAP-defined hepatic steatosis and cardiometabolic risk in rheumatoid arthritis: a post-hoc analysis of the FRANCIS randomized trial.

A N Saidi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.